Email this article New prospects in the use of Kadcyla® in breast cancer
- Authors: Dashyan G.A.1,2, Semiglazov V.F.1,2, Krivorot’ko P.V.1,2, Paltuev R.M.3,4, Topuzov E.E.5,6, Semiglazova T.Y.1,2, Zhil’tsova E.K.1,2, Donskikh R.V.1,2, Tabagua T.T.1,2, Apollonova V.S.1,2
-
Affiliations:
- N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia
- 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, Russia
- Railway Clinical Hospital, OJSC “RZhD”
- 27 Mechnikov Prosp., Saint Petersburg, 195271, Russia
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
- 41 Kirochnaya St., Saint Petersburg, 191015, Russia
- Issue: Vol 11, No 4 (2015)
- Pages: 46-52
- Section: MAMMOLOGY. TREATMENT
- Published: 25.11.2015
- URL: https://ojrs.abvpress.ru/ojrs/article/view/458
- DOI: https://doi.org/10.17650/1994-4098-2015-11-4-46-52
- ID: 458
Cite item
Full Text
Abstract
As is known, the HER-2-expressing biological subtype of breast cancer (BC) is characterized by an aggressive course and has a poor
prognosis in the absence of specific treatment. Before the emergence of trastuzumab, 5-year overall survival in patients with the disseminated forms of BC was 20 % (median survival, 16–29 months), out of whom only 2–5 % were long-term survivors. Addition of trastuzumab, a humanized monoclonal antibody that binds selectively to HER-2 receptor on the surface of tumor cells, to first-line chemotherapy for HER-2-positive metastatic BC caused a considerable enhancement of therapeutic efficiency. When trastuzumab is incorporated into chemotherapy for metastatic BC, median progression-free survival and overall survival were 7.4 and 25.1 months (4.6 and 20.3 months without trastuzumab), respectively. Kadcyla® (T-DM1), an antibody-drug conjugate, represents a new approach to treating HER-2-positive metastatic BC. T-DM1 is characterized by the innovative and selective mechanism of action on the HER-2-positive tumor cells. Through this mechanism, T-DM1 leads to a double antitumor effect: a trastuzumab-mediated anti-HER-2 effect and a cytotoxic effect due to the selective transport of the potent antimitotic agent DM1 into the cytoplasm. This mechanism of action enhances the efficiency of antitumor therapy and reduces toxicity. Kadcyla® has been approved in the Russian Federation, as well as by the European Medicines Agency and the United States Food and Drug Administration as monotherapy in HER-2-positive inoperable locally advanced or metastatic BC patients previously treated with taxanes and / or trastuzumab.
About the authors
G. A. Dashyan
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, Russia
Author for correspondence.
Email: dgarik@mail.ru
Russian Federation
V. F. Semiglazov
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
P. V. Krivorot’ko
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
R. M. Paltuev
Railway Clinical Hospital, OJSC “RZhD”; 27 Mechnikov Prosp., Saint Petersburg, 195271, RussiaRussian Federation
E. E. Topuzov
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia; 41 Kirochnaya St., Saint Petersburg, 191015, RussiaRussian Federation
T. Yu. Semiglazova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
E. K. Zhil’tsova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
R. V. Donskikh
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
T. T. Tabagua
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
V. S. Apollonova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
References
Supplementary files
